PMID- 24081946 OWN - NLM STAT- MEDLINE DCOM- 20140107 LR - 20240318 IS - 1527-7755 (Electronic) IS - 0732-183X (Print) IS - 0732-183X (Linking) VI - 31 IP - 32 DP - 2013 Nov 10 TI - Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer. PG - 4060-6 LID - 10.1200/JCO.2012.45.1278 [doi] AB - PURPOSE: Etirinotecan pegol (NKTR-102) is a unique, long-acting topoisomerase-I inhibitor with prolonged systemic exposure to SN38 (7-ethyl-10-hydroxycamptothecin), the active metabolite of irinotecan. This randomized phase II trial investigated two dosing schedules of etirinotecan pegol in patients with platinum-resistant/refractory ovarian carcinoma. PATIENTS AND METHODS: A total of 71 eligible patients were randomly assigned to receive etirinotecan pegol 145 mg/m(2) every 14 or 21 days until progression or unacceptable adverse events (AEs). The primary end point was objective response rate (ORR) by RECIST (version 1.0). Secondary end points included response by Gynecologic Cancer Intergroup criteria, duration of ORR, progression-free survival (PFS), and overall survival (OS). RESULTS: The overall confirmed ORR was 20% (95% CI, 10% to 30%): 20% for once every 14 days, and 19% for once every 21 days. Median response duration was 4.1 months for once every 14 days and 4.0 months for once every 21 days. Median PFS for every 14 and every 21 days was 4.1 and 5.3 months, respectively, and median OS was 10.0 and 11.7 months, respectively. Etirinotecan pegol was well tolerated, with the most common grade 3 to 4 AEs being dehydration (24%) and diarrhea (23%). Diarrhea, dehydration, nausea, and neutropenia were less frequent with the schedule of once every 21 days than with that of once every 14 days. CONCLUSION: Both schedules of etirinotecan pegol showed activity in patients with heavily pretreated ovarian cancer, with encouraging ORR and PFS rates. The schedule of once every 21 days was better tolerated and had slightly longer PFS and OS rates. The treatment schedule of etirinotecan pegol 145 mg/m(2) once every 21 days was selected for the expanded phase II study and is preferred for future phase III studies. These findings provide support to directly compare etirinotecan pegol versus one of the approved drugs (eg, pegylated liposomal doxorubicin or topotecan) in platinum-resistant ovarian cancer. FAU - Vergote, Ignace B AU - Vergote IB AD - Ignace B. Vergote, University Hospital Leuven, Leuven; Christine Gennigens, Centre Hospitalier Universitaire de Liege, Liege; Luc Y. Dirix, Gasthuis Zusters Antwerpen, Antwerp, Belgium; Agustin Garcia, University of Southern California Norris Comprehensive Cancer Center and Hospital, Los Angeles; John Micha, Gynecologic Oncology Associates, Newport Beach; Emad N. Ibrahim, Beaver Medical Group, Redlands; Abraham C.F. Leung, Carol Zhao, and Raoudha Soufi-Mahjoubi, Nektar Therapeutics, San Francisco, CA; Charles Pippitt, Piedmont Hematology Oncology Associates, Winston Salem, NC; Johanna Bendell, Sarah Cannon Research Institute, Nashville, TN; Daniel Spitz, Palm Beach Cancer Institute, West Palm Beach, FL; Nicholas Reed, Beatson Oncology Centre, Glasgow; Graham Dark, Freeman Hospital, Newcastle upon Tyne; Chris Poole, University Hospital Coventry, Coventry; Gordon Rustin, Mount Vernon Hospital, Northwood, United Kingdom; Paula M. Fracasso and Linda Duska, University of Virginia Health System, Charlottesville, VA; and Vincent A. Armenio, Pharma Resource, Providence, RI. FAU - Garcia, Agustin AU - Garcia A FAU - Micha, John AU - Micha J FAU - Pippitt, Charles AU - Pippitt C FAU - Bendell, Johanna AU - Bendell J FAU - Spitz, Daniel AU - Spitz D FAU - Reed, Nicholas AU - Reed N FAU - Dark, Graham AU - Dark G FAU - Fracasso, Paula M AU - Fracasso PM FAU - Ibrahim, Emad N AU - Ibrahim EN FAU - Armenio, Vincent A AU - Armenio VA FAU - Duska, Linda AU - Duska L FAU - Poole, Chris AU - Poole C FAU - Gennigens, Christine AU - Gennigens C FAU - Dirix, Luc Y AU - Dirix LY FAU - Leung, Abraham C F AU - Leung AC FAU - Zhao, Carol AU - Zhao C FAU - Soufi-Mahjoubi, Raoudha AU - Soufi-Mahjoubi R FAU - Rustin, Gordon AU - Rustin G LA - eng GR - P30 CA044579/CA/NCI NIH HHS/United States PT - Clinical Trial, Phase II PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial DEP - 20130930 PL - United States TA - J Clin Oncol JT - Journal of clinical oncology : official journal of the American Society of Clinical Oncology JID - 8309333 RN - 0 (Antineoplastic Agents) RN - 0 (Heterocyclic Compounds, 4 or More Rings) RN - 0 (Platinum Compounds) RN - 3WJQ0SDW1A (Polyethylene Glycols) RN - LJ16641SFT (etirinotecan pegol) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Antineoplastic Agents/*administration & dosage/adverse effects MH - Carcinoma, Ovarian Epithelial MH - Disease-Free Survival MH - *Drug Resistance, Neoplasm/drug effects MH - Female MH - Heterocyclic Compounds, 4 or More Rings/*administration & dosage/adverse effects MH - Humans MH - Kaplan-Meier Estimate MH - Middle Aged MH - Neoplasm Recurrence, Local/*drug therapy/mortality MH - Neoplasms, Glandular and Epithelial/*drug therapy/mortality MH - Ovarian Neoplasms/*drug therapy/mortality MH - Platinum Compounds/therapeutic use MH - Polyethylene Glycols/*administration & dosage/adverse effects MH - Treatment Outcome PMC - PMC4878105 COIS- Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article. EDAT- 2013/10/02 06:00 MHDA- 2014/01/08 06:00 PMCR- 2013/09/30 CRDT- 2013/10/02 06:00 PHST- 2013/10/02 06:00 [entrez] PHST- 2013/10/02 06:00 [pubmed] PHST- 2014/01/08 06:00 [medline] PHST- 2013/09/30 00:00 [pmc-release] AID - JCO.2012.45.1278 [pii] AID - 51278 [pii] AID - 10.1200/JCO.2012.45.1278 [doi] PST - ppublish SO - J Clin Oncol. 2013 Nov 10;31(32):4060-6. doi: 10.1200/JCO.2012.45.1278. Epub 2013 Sep 30.